Furthermore, the combination of GLPG0259, an inhibitor of PRAK, with EV-derived miRNAs specifically targeting PRAK exhibits promising potential in mitigating neuroinflammation observed in neurodegenerative disorders like PD. Here, MAPKAPK5 is linked to Parkinson disease.